NCT05664555View on ClinicalTrials.gov

Dose Optimization for Safe and Efficient Fluorescein Angiography (DOSE Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Retinal Disease
Interventions
DRUG

Fluorescein Sodium

Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.

Trial Locations (1)

13620

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER